A third blind person has received a brain implant that bypasses the eyes and optic nerve entirely, sending patterns of artificial sight directly to the visual cortex. The surgery took place at Rush University Medical Center in Chicago. The device, called the Intracortical Visual Prosthesis or ICVP, is built by a research consortium led by Illinois Institute of Technology, which announced the third successful implantation on 7 May 2026. The implant consists of 34 small wireless stimulators carrying 544 electrodes that sit on the surface of the visual cortex. The surgical procedure has now held across three patients, moving the system out of single-patient feasibility and into early multi-patient clinical work.

How the device works

ICVP is the first vision-restoration brain implant to use a cluster of small wireless devices coordinated together rather than a single larger tethered array. Each stimulator carries a small number of electrodes, and the cluster acts in coordination to produce a denser, more distributed pattern of visual signals than any single device could deliver. The current 34-stimulator, 544-electrode configuration is denser than the earlier 25-stimulator, 400-electrode build that has been in long-term testing since the first ICVP implantation two years ago.

ICVP is designed for people whose blindness sits in the eye or optic nerve itself, where the visual pathway is broken before any signal reaches the brain. For these patients, retinal devices and pharmaceutical treatments have no anatomical target. Direct cortical stimulation is the only remaining route to engineered sight.

After a four-week recovery period, training will begin at The Chicago Lighthouse’s Hilton Center for Prosthetic Research, the research home for the ICVP clinical trial.

The consortium behind it

Philip R. Troyk, executive director of the Pritzker Institute of Biomedical Science and Engineering at Illinois Institute of Technology, is the principal investigator. The consortium includes Johns Hopkins University’s Wilmer Eye Institute, the University of Chicago, the University of Texas at Dallas, Rush University Medical Center as the surgical site, The Chicago Lighthouse as the research and training home, and contract suppliers Microprobes for Life Science and Sigenics. The programme has been funded primarily through NIH BRAIN Initiative grants over nearly three decades, a model that resembles the early BrainGate consortium and contrasts with the venture-backed clinical pathway most other brain-implant companies are following.

Three other vision-restoration platforms

ICVP is not alone in the clinic. Three other vision-restoration programmes are at clinical or regulatory milestones in 2026.

Belgian startup ReVision Implant received FDA Breakthrough Device Designation for its Occular visual cortical prosthesis in March 2026. A first short-term clinical trial during scheduled brain surgery is planned for October 2026, with early-stage trials in blind volunteers expected in summer 2027.

Neuralink’s Blindsight cortical implant is targeted for first-in-human implantation during 2026 per Elon Musk’s public statements, potentially in the United Arab Emirates. Like ICVP, Blindsight will stimulate the visual cortex directly.

Science Corporation took a different anatomical bet. Its PRIMA implant is a small photovoltaic chip placed under the retina rather than in the brain, designed to restore some vision to patients with geographic atrophy from age-related macular degeneration, where parts of the retina remain intact. Science Corporation submitted PRIMA for European CE Mark approval in June 2025 with a target of EU approval in mid-2026.

Four programmes, one therapeutic outcome: restoring some functional sight to patients who cannot currently see. The architecture choice determines who the implant can help, how risky the surgery is, and how readily the device can be manufactured at scale. It is a commercial decision as much as a technical one.

What to watch

The next ICVP-specific signal is the training data that emerges from the Hilton Center after the four-week recovery period. That data will indicate whether the third implant achieves the perceptual resolution the design predicts. Beyond ICVP, the comparable signals are PRIMA’s CE Mark decision in mid-2026, the first publicly disclosed Blindsight implant whenever it occurs, and any clinical readout from ReVision Implant’s October 2026 surgical-window trial. The cortical vision restoration field will look materially different by the end of 2026.

Sources

• Third Successful Implantation of Wireless Visual Prosthesis Brain Implant (Illinois Institute of Technology, 7 May 2026)
• Third successful implantation of wireless visual prosthesis brain implant (EurekAlert, 7 May 2026)
• Brain implant delivers artificial sight to people with complete blindness (Engineering & Technology Magazine, 8 May 2026)
• New wireless visual cortex implant helps restore artificial sight (Interesting Engineering)
• Intracortical Visual Prosthesis Project (The Chicago Lighthouse)
• Belgian Neurotech Startup ReVision Implant Secures FDA Breakthrough Status (Eyewire+)
• Science Submits CE Mark Application for PRIMA Retinal Implant (Science Corporation)
• Elon Musk announces Neuralink’s first human implant of Blindsight coming this year (MobiHealthNews)